[Inflammatory Bowel Disease is a chronic condition characterized by inflammation in the gastrointestinal tract. The primary cause of IBD is an overreactive immune response, where immune cells mistakenly attack the gut lining, leading to prolonged inflammation and tissue damage. A key regulator of such inflammation, Interleukin-10 (Il-10), plays a fundamental role in modulating inflammation and maintaining cell homeostasis by protecting the body from an uncontrolled immune response by inhibiting pro-inflammatory cytokines like TNF-α and IL-6. However, Il-10’s therapeutic potential is severely limited by its structural instability due to its homodimer nature and easy degradation within the body. This instability reduces its effectiveness as a long-term treatment leaving patients with limited options for prolonged IBD treatments. To address this issue, we propose a probiotic-based approach, engineering a mutated more stable form of Il-10 (MIL-10). Delivered through dairy products like yogurt, this system would provide MIL-10 production in reaction to pro-inflammatory cytokines, ensuring sustained inflammation control for diseases like IBD. ]
[Sample text here]
[Sample text here]
[Sample text here]